Treatment for relapsed/refractory ailment should be resolved according to prior therapy in addition to The main reason why the initial procedure was no longer ideal (e.g., refractoriness vsDuvelisib was the 2nd PI3K inhibitor authorized with the FDA, also based on a phase III randomized trial.one hundred thirty The efficacy and basic safety profile